Company
Merck & Co Inc
NYSE:MRK
Merck & Co Inc is a global healthcare company. The company offers health solutions through its prescription medicines, including biological therapies, vaccines and animal health products.
138 stories · page 1 of 2
Merck’s COVID-19 pill authorised for emergency use by US FDA
The Emergency Use Authorisation is for treatment of high-risk adults with mild to moderate COVID-19
Merck's new COVID pill gets the US regulatory green light - but only just
The Food & Drug Administration sign-off light follows the decision by regulators in the UK and EU to allow molnupiravir to be prescribed on an emergency use basis
Merck’s COVID drug not as effective as first thought
The company had reported it reduced the risk of serious illness by half in October
Merck Covid-19 treatment approved in UK as infection rate soars
Molnupiravir will be branded as Lagevrio in Britain
Antiviral drug from Merck slashes risk of Covid hospitalization or death
An application is being made to the US regulator for emergency use authorisation for what will be the first antiviral on the market to treat Covid-19
US stocks close higher on Merck's new COVID-19 oral treatment announcement
The drugmaker said the oral antiviral treatment reduced the risk of hospitalization or death by 50% for patients with mild or moderate cases
Archive
Traders send the S&P 500 to a record on busiest day of earnings season
11 of the S&P 500 components are scheduled to issue quarterly reports
Merck to invest US$1bn in Seattle Genetics as part of oncology collaboration agreement
Merck will buy 5mln shares at US$200 each plus other payments to study Seattle Genetics' candidate with its Keytruda treatment
Investments and investor services
IPO Roundup: Peloton Therapeutics gobbled up by Merck just as it prepared to go public
The sale provides Peloton shareholders with $1.05 billion in cash, with a possible $1.15 more if its treatments hit certain milestones
Hemispherx Biopharma says FDA authorizes study using aspirin and flagship drug ampligen to treat prostate cancer
The Phase 2 study will be carried out at the Roswell Park Comprehensive Cancer Center in Buffalo and involve up to 60 patients
Hemispherx sees potential commercialization of flagship drug ampligen for Chronic Fatigue Syndrome
The company said results of a recent Stanford University diagnostic test of 20 patients with MF/CFS were 'impressive'
IPO Roundup: Tradeweb Markets and Silk Road Medical jump in market debuts, while NGM Biopharmaceuticals dips
Despite a slow start, 2019 is shaping up to be a stellar year for US initial public offerings with strong investor appetite for new issues
AstraZeneca granted Breakthrough Therapy Designation for rare genetic condition treatment
A breakthrough therapy designation is designed to expedite the development and review of medicines that are intended to treat a serious condition and have shown promise in early-stage clinical trials
Hemispherx Biopharma takes cancer war to new stage with drug Ampligen
A series of trials underway at major cancer research hospitals are evaluating the company's flagship cancer drug Ampligen
CytoDyn presses forward with HIV treatment after Phase 3
Leronlimab is an antiviral agent candidate with fewer side effects, lower toxicity and less frequent doses than daily HIV therapies now in use
AFTER-HOURS MOVERS: Kraft shares plummet after earnings miss, discloses SEC subpoena
Also moving after-hours on Thursday was Zillow, which announced CEO Spencer Rascoff will step down
Hemispherx announces start of Merck-supported ovarian cancer clinical drug trial
Last month, tests started for combination therapy targeting metastatic, triple-negative breast cancer
CytoDyn says it’s on the cusp of a breakthrough HIV treatment after Phase 3 trial
Leronlimab shows promise as an antiviral agent with fewer side effects, lower toxicity and less frequent doses than daily HIV therapies now in use
Investments and investor services
MIDDAY MOVERS: Twitter pounded after being called the Harvey Weinstein of social media by Andrew Left
Billionaire icon Carl Icahn raises stake in Newell Brands Inc
Moderna is biggest biotech IPO, draws $604 million despite turbulent market
The Cambridge biotech, which is developing novel messenger RNA technology, priced at the midpoint of expected range in a sign of resiliency but shares declined in their first few minutes of trading
Biotech companies dominate at Dawson James Securities Small Cap Growth Conference
Interpace Diagnostics, Hemispherx Biopharma among the standouts presenting at the investor-focused event
IPO Roundup: Urovant Sciences, EdtechX and Remora Royalty to tap the capital markets, while Volvo Cars drops IPO
All eyes are on hedge-funder-turned-biotech whiz kid Vivek Ramaswamy who is launching his fifth biotech company Urovant Sciences
Hardware & electrical equipment
IPO Roundup: Search software company Elastic to raise US$100mln as competition with Amazon heats up
The California-based company’s Elasticsearch open-source software is used by customers like Uber, Walgreens, Adobe Systems, Merck and Sprint
EARLY MOVERS: Ambarella tanks in pre-market as it lowers outlook but American Outdoor Brands Corp stock fires up
Also in focus before the New York bell was Publix and Merck & Co..
Oppenheimer reiterates Outperform rating on BioLineRx after positive data from GENISIS study of BL-8040
Meanwhile, Maxim was also pleased with the study of BL-8040 as a stem cell mobilizer for bone marrow transplants moving ahead of schedule
BioLineRx's collaboration with Merck supports the potential of BL-8040 in ‘difficult to treat cancers,’ says Maxim
The BL-8084 platform continues to make progress across multiple indications and data from several studies is expected in 2018
Merck's 2Q earnings beat Street with sales turbocharged by cancer drug Keytruda
Drug giant raised its full-year guidance to a range of US$4.22 and US$4.30 a share compared with US$4.16 to US$4.28 a share expected last quarter
Two of AstraZeneca’s key cancer drugs win speedy approvals in Japan
Lynparza and Imfinzi are likely to play an important role if AstraZeneca is to hit its target of generating annual sales of US$45bn by 2023
AstraZeneca’s Lynparza drug sails through late-stage ovarian cancer study
The drug has already been approved for later use in ovarian and breast cancer patients, but the SOLO-1 trial has sowed it could be useful as a first-line treatment
AstraZeneca and Eli Lilly halt late-stage Alzheimer’s study as drug shows no sign of working
AstraZeneca and Lilly’s lanabecestat drug can be added to the list of failed Alzheimer’s treatments; in fact, 99% of all drugs developed to treat the disease have failed clinical trials in the past ten years
AstraZeneca and Merck present data from prostate cancer trial at ASCO 2018
The data showed that the combination of Lynparza and abiraterone can help patients with a specific form of prostate cancer to live for longer without their disease getting worse
Merck milestone payment helps Aduro Biotech to beat analyst estimates with 1Q results
Oppenheimer says company's cash position 'should continue to provide operational freedom'
Merck posts better-than-expected 1Q profits due to sales of its drug Keytruda
On an adjusted basis, the pharmaceutical giant earned US$1.05 per share, which beat the consensus estimate of $0.99
Investments and investor services
Dow falls on broad pullback, but tech rally keeps Nasdaq positive
Generally speaking, it has been a good earnings season so far for US companies, but a couple of disappointing announcements have scared investors who are already a little twitchy
Procter & Gamble acquires German Merck’s consumer health unit for US$4.2bln
P&G will add Merck's vitamins and supplements to its product line
Merck shares pop as its Keytruda drug results power ahead of Bristol-Myers, Roche
The immunotherapies boost patient survival rates, studies show
Investments and investor services
US benchmarks close higher as earnings season points to strong growth
US stocks advanced as traders remain bullish about the corporate earnings season
US benchmarks pare gains in final minutes but close higher
A loom at the US and Canadian markets as the day progresses..
Merck & Co shares rise thanks to success of Phase 3 lung cancer trial
Patients treated with Keytruda lived significantly longer than those who received chemotherapy
Leucadia National, Merck & Co, Franklin Resources, Menlo Therapeutics - PRE-MARKET
Proactive takes a look at some movers and shakers before the bell on Monday April 9
Cidara soars in pre-market as lead antifungal drug breezes through mid-stage trial
Rezafungin was safe and well tolerated in patients with candidemia and/ or invasive candidiasis, while the data also showed evidence of the drug’s efficacy
MARKET MOVERS: DBV Technologies, InspireMD, Tetraphase...
There were a few mid- and late-stage trial failures which weighed on some pharma stocks on Wednesday...
Merck & Co's quarterly loss widens as it takes US$2.6bn hit due to US tax changes
Fourth quarter earnings beat forecasts but revenues missed
Merck shares continue to rise after successful lung cancer trial
Results from a large-scale trial showed a combination of Merck’s Keytruda drug and an older type of chemotherapy helped newly-diagnosed cancer patients live longer and stop the disease from advancing
Wall Street shares take a bath, but TSX up
Wall Street shares went lower on Monday as the shine came off the rally last week
Builders and building materials
Lennar Corp, CalAtlantic Group, Merck & Co, Enzymotec - AFTER HOURS
A look at what's happening before the bell in new York
Nasdaq Composite and S&P 500 storm to new highs, driven by tech stocks
The Nasdaq missed out on yesterday's advance but made up for lost time today
Merck shares slip premarket after hiking outlook following mixed bag of third quarter results
For the full year 2017, the drug giant raised its adjusted EPS outlook to US$3.91 to US$3.97 from US$3.76 to US$3.88 and lifted its revenue outlook to US$40.0bn to US$40.5bn from US$39.4bn to US$40.4bn
Archive
Lloyds Banking looking to put its trials behind it
PPI, the HBOS acquisition and now the prospect of a rate rise hitting the mortgage market; it's all a bit of a trial for Lloyds
Lloyds, Barclays and RBS under the microscope with release of third quarter earnings
The week ahead includes third quarter earnings from Lloyds, Barclays and RBS along with trading updates from Shire, IAG and GSK
Merck discontinues one of its hepatitis C virus drug development programs
This decision was made based on a review of available Phase 2 efficacy data and in consideration of the evolving marketplace and the growing number of treatment options available for patients with chronic HCV infection
Celgene says US FDA places holds on clinical trials for cancer checkpoint inhibitor being developed with AstraZeneca
Celegene said the FDA's decision was due to risks seen in other trials for another checkpoint inhibitor, Merck & Co.'s anti-PD-1 antibody pembrolizumab, in combination with immunomodulatory agents
German drug giant Merck KGaA considering sale of US$1bn consumer health unit to meet financial targets
The consumer business -- whose brands include nutritional supplements Seven Seas and Bion and decongestant Nasivin – has been seen as lacking critical scale by analysts for a number of years.
AstraZeneca ovarian cancer drug approved for wider use
Lynparza was initially approved to be given to women with advanced ovarian cancer who had stopped responding to three rounds of chemotherapy
Merck & Co cuts full year profit guidance; agrees drug collaboration with AstraZeneca
Merck & Co is yet to determine the full impact of the ‘Petya’ cyber attack in June that disrupted operations
Oil giants Exxon and Chevron find market hard to please - PRE-MARKET
Also featured: American Airlines and Merc & Co Inc